Skip to main content
NewslettersWatchlist

Aeterna Zentaris Inc(AEZS-T)
TSX

Today's Change
Real-Time Last Update
Day Low11.03
Day High11.49
Open:11.03
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Automated Summaries - The Globe and Mail
Closing Bell: Aeterna Zentaris Inc up on Tuesday (AEZS)
AI-generated - The Globe and Mail
AEterna Zentaris: Top 10 Undervalued Healthcare Sector Stocks on TSX (AEZS)
AI-generated - The Globe and Mail
AEterna Zentaris: Stocks trading at Less Than Cash Value on TSX (AEZS)
AI-generated - The Globe and Mail
AEterna Zentaris: Top 10 Undervalued Biotechnology Industry Stocks (AEZS)
AI-generated - The Globe and Mail
AEterna Zentaris: Top 10 Undervalued Healthcare Sector Stocks on TSX (AEZS)
AI-generated - The Globe and Mail
AEterna Zentaris: Top 25 Undervalued Toronto Stock Exchange Stocks (AEZS)
GlobeNewswire
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
GlobeNewswire
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
AI-generated - The Globe and Mail
AEterna Zentaris: Stocks trading at Less Than Cash Value on TSX (AEZS)
Baystreet
Shortened Week Due to Easter Holiday
GlobeNewswire
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
GlobeNewswire
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
AI-generated - The Globe and Mail
AEterna Zentaris: Stocks trading at Less Than Cash Value on TSX (AEZS)
GlobeNewswire
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro
AI-generated - The Globe and Mail
AEterna Zentaris: Top 10 Undervalued Biotechnology Industry Stocks (AEZS)
AI-generated - The Globe and Mail
AEterna Zentaris: Top 10 Undervalued Healthcare Sector Stocks on TSX (AEZS)
AI-generated - The Globe and Mail
AEterna Zentaris: Stocks trading at Less Than Cash Value on TSX (AEZS)
The Globe and Mail
Market movers: Stocks that saw action on Thursday - and why
GlobeNewswire
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company
AI-generated - The Globe and Mail
AEterna Zentaris: Top 10 Undervalued Biotechnology Industry Stocks (AEZS)
The Globe and Mail
‘Net-net’ stocks soared in 2023. What is on the list for 2024?
GlobeNewswire
Aeterna Zentaris Reports Third Quarter 2023 Financial Results
AI-generated - The Globe and Mail
AEterna Zentaris: Stocks trading at Less Than Cash Value on TSX (AEZS)
AI-generated - The Globe and Mail
AEterna Zentaris: Top 10 Undervalued Biotechnology Industry Stocks (AEZS)
AI-generated - The Globe and Mail
AEterna Zentaris: Top 10 Undervalued Growth Stocks on TSX (AEZS)
AI-generated - The Globe and Mail
AEterna Zentaris: Top 25 Undervalued Toronto Stock Exchange Stocks (AEZS)
GlobeNewswire
Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference
Baystreet
Stocks in play: Aeterna Zentaris Inc.
GlobeNewswire
Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference
GlobeNewswire
Aeterna Zentaris Reports Second Quarter 2023 Financial Results
The Globe and Mail
AEterna Zentaris: Top 10 Undervalued Biotechnology Industry Stocks (AEZS)
The Globe and Mail
AEterna Zentaris: Stocks trading at Less Than Cash Value on TSX (AEZS)

Profile

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland which generates key revenue, Ireland, Denmark, and others.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.